Abstract:Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the progressive loss of dopaminergic (DAnergic) neurons in the substantia nigra and decreased dopamine (DA) levels, which lead to both motor and non-motor symptoms. Conventional PD treatments aim to alleviate symptoms, but do not delay disease progression. PD gene therapy offers a promising approach to improving current treatments, with the potential to alleviate significant PD symptoms and cause fewer adverse effects than conventional therapies. DA replacement approaches and DA enzyme expression do not slow disease progression. However, DA replacement gene therapies, such as adeno-associated virus (AAV)–glutamic acid decarboxylase (GAD) and L-amino acid decarboxylase (AADC) gene therapies, which increase DA transmitter levels, have been demonstrated to be safe and efficient in early-phase clinical trials. Disease-modifying strategies, which aim to slow disease progression, appear to be potent. These include therapies targeting downstream pathways, neurotrophic factors, and midbrain DAnergic neuronal factors, all of which have shown potential in preclinical and clinical trials. These approaches focus on maintaining the integrity of DAnergic neurons, not just targeting the DA transmitter level itself. In particular, critical midbrain developmental and maintenance factors, such as Nurr1 and Foxa2, can interact synergistically with neighboring glia, in a paracrine mode of action, to protect DAnergic neurons against various toxic factors. Similar outcomes could be achieved by targeting both DAnergic neurons and glial cells with other candidate gene therapies, but in-depth research is needed. Neurotrophic factors, such as neurturin, the glial-cell-line-derived neurotrophic factor (GDNF), the brain-derived neurotrophic factor (BDNF), and the vascular endothelial growth factor (VEGF), are also being investigated for their potential to support DAnergic neuron survival. Additionally, gene therapies targeting key downstream pathways, such as the autophagy–lysosome pathway, mitochondrial function, and endoplasmic reticulum (ER) stress, offer promising avenues. Gene editing and delivery techniques continue to evolve, presenting new opportunities to develop effective gene therapies for PD.

AAV-aMTD-Parkin, a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson's and Alzheimer's diseases

An Accelerated Parkinson’s Disease Monkey Model Using AAV-α-synuclein Plus Poly(adp-Ribose)

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside

Therapeutic Efficacy Of Aav8-Mediated Intrastriatal Delivery Of Human Cerebral Dopamine Neurotrophic Factor In 6-Ohda-Induced Parkinsonian Rat Models With Different Disease Progression

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

AAV-based in vivo gene therapy for neurological disorders

Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system

Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons

Optimized AAV capsids for diseases of the basal ganglia show robust potency and distribution in adult nonhuman primates

Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases

Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system

BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment

A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency

Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance

Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS